Literature DB >> 1366536

Environmental effects on protein glycosylation.

C F Goochee1, T Monica.   

Abstract

Cultured mammalian cells are being used to produce proteins for therapeutic and diagnostic use because of their ability to perform complex post-translational modifications, including glycosylation. The oligosaccharide moieties can play an important role in defining several biological properties of glycoproteins, including clearance rate, immunogenicity, and biological specific activity. There is a growing interest in defining the factors that influence glycosylation, including the cell culture environment. In this review we organize the published data from in vitro cell culture and tissue culture studies that demonstrate direct effects of the culture environment on N-linked glycosylation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1366536     DOI: 10.1038/nbt0590-421

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  40 in total

Review 1.  Filamentous fungi as production organisms for glycoproteins of bio-medical interest.

Authors:  M Maras; I van Die; R Contreras; C A van den Hondel
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

Review 2.  Structure-immunogenicity relationships of therapeutic proteins.

Authors:  Suzanne Hermeling; Daan J A Crommelin; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

3.  Biosynthesis of protein products by animal cells. Are growth and non-growth associated concepts valid or useful?

Authors:  J P Barford; P J Phillips; C P Marquis; C Harbour
Journal:  Cytotechnology       Date:  1996-06       Impact factor: 2.058

4.  Effect of culture temperature on a recombinant CHO cell line producing a C-terminal α-amidating enzyme.

Authors:  K Furukawa; K Ohsuye
Journal:  Cytotechnology       Date:  1998-03       Impact factor: 2.058

5.  Genetic engineering of α2,6-sialyltransferase in recombinant CHO cells and its effects on the sialylation of recombinant interferon-γ.

Authors:  L Monaco; A Marc; A Eon-Duval; G Acerbis; G Distefano; D Lamotte; J M Engasser; M Soria; N Jenkins
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

6.  Optimization of the medium perfusion rate in a packed-bed bioreactor charged with CHO cells.

Authors:  F Meuwly; U von Stockar; A Kadouri
Journal:  Cytotechnology       Date:  2005-06-16       Impact factor: 2.058

7.  The roles of a process development group in biopharmaceutical process startup.

Authors:  Charles F Goochee
Journal:  Cytotechnology       Date:  2002-01       Impact factor: 2.058

8.  Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells.

Authors:  François Lefloch; Bertrand Tessier; Sébastien Chenuet; Jean-Marc Guillaume; Pierre Cans; Jean-Louis Goergen; Annie Marc
Journal:  Cytotechnology       Date:  2006-12-29       Impact factor: 2.058

9.  Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains.

Authors:  Dmitriy Balabashin; Elena Kovalenko; Viktoria Toporova; Teimur Aliev; Anna Panina; Elena Svirshchevskaya; Dmitry Dolgikh; Mikhail Kirpichnikov
Journal:  Cytotechnology       Date:  2014-06-18       Impact factor: 2.058

10.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.